Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zeneca Group plc (NYSE ticker ZEN) -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (17)	6/18/1998 12:28:00 PM
From: DavesM	Read Replies (1) \| Respond to of 75

So I finally got around to the yearly report on ZEN Found some interesting things on the oncology front: (1.) Faslodex in Phase III testing, this drug a selective anti-oestrogen, for breast cancer. They claim that this drug also has a bone-sparing effect (ZEN's replacement for Tamoxifin which goes/is off patent?). (2.) ZD 0101, an anti angiogenesis drug? in Phase II testing. They explain that the drug prevents blood vessels forming in a tumor. I looked around, and though I could find that the drug was in human testing, all I could find was that it was in Phase I testing.